NCT05979363View on ClinicalTrials.gov

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Plasma Cell Leukemia
Interventions
BIOLOGICAL

anti-BCMA CAR-T

Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.

DRUG

VRD-based regimen

Bortezomib, Lenalidomide and Dexamethasone

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER